The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.